Stryker Corporation $SYK Shares Acquired by MBL Wealth LLC

MBL Wealth LLC lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 9.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,173 shares of the medical technology company’s stock after buying an additional 103 shares during the quarter. MBL Wealth LLC’s holdings in Stryker were worth $464,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Wealthcare Advisory Partners LLC grew its position in shares of Stryker by 113.0% during the second quarter. Wealthcare Advisory Partners LLC now owns 2,590 shares of the medical technology company’s stock worth $1,025,000 after buying an additional 1,374 shares in the last quarter. Talbot Financial LLC grew its position in shares of Stryker by 22.4% during the second quarter. Talbot Financial LLC now owns 53,747 shares of the medical technology company’s stock worth $21,264,000 after buying an additional 9,827 shares in the last quarter. Clarius Group LLC grew its position in shares of Stryker by 4.1% during the second quarter. Clarius Group LLC now owns 2,111 shares of the medical technology company’s stock worth $835,000 after buying an additional 84 shares in the last quarter. Penobscot Investment Management Company Inc. grew its position in shares of Stryker by 0.9% during the second quarter. Penobscot Investment Management Company Inc. now owns 42,391 shares of the medical technology company’s stock worth $16,771,000 after buying an additional 390 shares in the last quarter. Finally, AMF Tjanstepension AB boosted its holdings in Stryker by 319.9% in the second quarter. AMF Tjanstepension AB now owns 193,817 shares of the medical technology company’s stock valued at $76,697,000 after purchasing an additional 147,663 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on SYK shares. Evercore ISI upped their price target on Stryker from $390.00 to $415.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. Rothschild Redb raised Stryker to a “hold” rating in a report on Thursday, September 18th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a report on Saturday, September 27th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Finally, Needham & Company LLC upped their price target on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $430.33.

Stryker Price Performance

Stryker stock opened at $370.59 on Friday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The business has a 50 day simple moving average of $382.81 and a 200-day simple moving average of $378.93. The stock has a market capitalization of $141.68 billion, a PE ratio of 49.08, a price-to-earnings-growth ratio of 2.67 and a beta of 0.94.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same quarter in the prior year, the business earned $2.81 earnings per share. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s dividend payout ratio is presently 44.50%.

Insider Buying and Selling at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.